Results 251 to 260 of about 281,370 (287)

A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer

British Journal of Cancer, 2023
This study aimed to elucidate the clinicopathological and molecular features of HER2-amplified and HER2-low colorectal cancers (CRCs). We also characterised HER2 expression statuses in CRCs focusing on their intratumoral heterogeneity and alterations in metastatic lesions to establish practical HER2 status assessment.We evaluated 1009 CRCs for HER2 ...
Taiki Hashimoto, Daisuke Takayanagi, Junpei Yonemaru, Tomoaki Naka, Kengo Nagashima, Erika Machida, Takashi Kohno, Yasushi Yatabe, Yukihide Kanemitsu, Ryuji Hamamoto, Atsuo Takashima, Kouya Shiraishi, Shigeki Sekine   +12 more
openaire   +2 more sources

Loss of HER2 after HER2-targeted treatment

Breast Cancer Research and Treatment, 2019
HER2 expression has been reported to be discordant between primary tumor and metastatic tissue.HER2 discordance and relation to HER2-targeted treatment was investigated in 227 patients with primary breast cancer.HER2 discordance between primary biopsy and second biopsy after neoadjuvant or adjuvant treatment was observed in 20.7%.
Tanja Ignatov, Franceska Gorbunow, Holm Eggemann, Olaf Ortmann, Atanas Ignatov   +4 more
openaire   +2 more sources

Truncated HER2: implications for HER2-targeted therapeutics

Drug Discovery Today, 2011
The HER2 receptor is currently one of the flagship therapeutic targets in clinical oncology. Trastuzumab, an antibody targeting HER2, has become a foundation of care in women with HER2-positive breast cancer. However, many women with metastatic breast cancer do not respond to trastuzumab-based therapy.
Radoslaw, Zagozdzon, William M, Gallagher, John, Crown   +2 more
openaire   +3 more sources

ISH-based HER2 diagnostics

Der Pathologe, 2020
A prerequisite for all HER2 directed therapies is the demonstration of HER2 receptor protein overexpression and/or gene amplification by in situ hybridization (ISH). ASCO and CAP have published several HER2 test guidelines over the past 15 years for both breast and gastric cancer. The latest version for breast cancer (2018) focuses on special issues of
Josef, Rüschoff, Iris, Nagelmeier, Bharat, Jasani, Oliver, Stoss   +3 more
openaire   +3 more sources

Designing HER2 vaccines

Seminars in Oncology, 2002
HER2/neu is a compelling cancer vaccine candidate because it is overexpressed on some cancer cells relative to normal tissues, it is known to be immunogenic in both animal models and in humans, and it is already known to be targetable by the antibody component of the immune system in the form of monoclonal antibody therapy with trastuzumab.
Teresa M, Foy, Gary R, Fanger, Susan, Hand, Catherine, Gerard, Claudine, Bruck, Martin A, Cheever   +5 more
openaire   +2 more sources